CSIMarket



Merck and Co Inc   (MRK)
Other Ticker:  
 
 

MRK's Income from Cont. Operations Growth by Quarter and Year

Merck And Co Inc 's Income from Cont. Operations results by quarter and year




MRK Income from Cont. Operations (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 3,387.00 -2,092.00 2,364.00
III Quarter September - 4,571.00 2,945.00 1,907.00
II Quarter June - 1,214.00 3,010.00 2,644.00
I Quarter March 4,313.00 3,186.00 3,219.00 2,862.00
FY   4,313.00 12,358.00 7,082.00 9,777.00



MRK Income from Cont. Operations first quarter 2022 Y/Y Growth Comment
Merck and Co Inc achieved in the first quarter 2022, above Company average Income from Cont. Operations growth of 35.37% year on year, to $ 4,313.00 millions.

Looking into first quarter 2022 results within Major Pharmaceutical Preparations industry 21 other companies have achieved higher Income from Cont. Operations growth. While Merck And Co Inc ' s Income from Cont. Operations rise of 35.37% ranks overall at the positon no. 714 in the first quarter 2022.




MRK Income from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - 32.96 %
III Quarter September - 55.21 % 54.43 % -2.6 %
II Quarter June - -59.67 % 13.84 % 54.08 %
I Quarter March 35.37 % -1.03 % 12.47 % 286.23 %
FY   - 74.5 % -27.56 % 57.87 %

Financial Statements
Merck And Co Inc 's first quarter 2022 Income from Cont. Operations $ 4,313.00 millions MRK's Income Statement
Merck And Co Inc 's first quarter 2021 Income from Cont. Operations $ 3,186.00 millions Quarterly MRK's Income Statement
New: More MRK's historic Income from Cont. Operations Growth >>


MRK Income from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - -25.9 % - 23.96 %
III Quarter September - 276.52 % -2.16 % -27.87 %
II Quarter June - -61.9 % -6.49 % -7.62 %
I Quarter March 27.34 % - 36.17 % 60.97 %
FY (Year on Year)   - 74.5 % -27.56 % 57.87 %




Income from Cont. Operations first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #22
Healthcare Sector #57
Overall #714

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
146.86 % 7.94 % -87.73 %
(Sep 30 2018)   (Dec. 30, 2010)
Income from Cont. Operations first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #22
Healthcare Sector #57
Overall #714
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
146.86 % 7.94 % -87.73 %
(Sep 30 2018)   (Dec. 30, 2010)

Income from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Merck And Co Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
770.19 % 29.37 % -94.94 %
IV. Quarter   (March 31, 2010)


MRK's I. Quarter Q/Q Income from Cont. Operations Comment
Merck and Co Inc achieved in the I. Quarter 2022 below company average Income from Cont. Operations jump of 27.34% quarter on quarter, to $ 4,313.00 millions.

Albeit the I. Quarter 2022 MRK's performance was beneath the average of 29.37 %, it has been yet good sign, as the I. Quarter surge, eclipses the % Income from Cont. Operations surge in the same quarter a year ago

Within Major Pharmaceutical Preparations industry 13 other companies have achieved higher Income from Cont. Operations quarter on quarter growth. While Merck And Co Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is 526.


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #14
Healthcare Sector #33
Overall #526
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #14
Healthcare Sector #33
Overall #526
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
770.19 % 29.37 % -94.94 %
IV. Quarter   (March 31, 2010)


MRK's I. Quarter Q/Q Income from Cont. Operations Comment
Merck and Co Inc achieved in the I. Quarter 2022 below company average Income from Cont. Operations jump of 27.34% quarter on quarter, to $ 4,313.00 millions.

I. Quarter 2022 Merck And Co Inc 's results appear to be paradoxical, even if lower than the average rise of 29.37 %, yet it presents real recovery compare to the % in the I. Quarter 2021 Melissa Hall, a business contributor situated in Chicago wrote.

Within Major Pharmaceutical Preparations industry 13 other companies have achieved higher Income from Cont. Operations quarter on quarter growth. While Merck And Co Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is 526.


Merck And Co Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Income from Cont. Operations 12 Months Ending $ 13,485.00 $ 12,358.00 $ 6,879.00 $ 5,253.00 $ 7,049.00
Y / Y Income from Cont. Operations Growth (TTM) 91.3 % 74.5 % -40.38 % -49.97 % -30.44 %
Year on Year Income from Cont. Operations Growth Overall Ranking # 430 # 480 # 1101 # 1781 # 1073
Seqeuential Income from Cont. Operations Change (TTM) 9.12 % 79.65 % 30.95 % -25.48 % -0.47 %
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # 714 # 155 # 245 # 2146 # 1115




Cumulative Income from Cont. Operations growth Comment
Merck And Co Inc saw improvement in Income from Cont. Operations growth trend, posting cumulative 12 months Income from Cont. Operations growth of 91.3% year on year, to $ 13,485 millions if the fiscal year would have ended in Mar 31 2022.
Merck And Co Inc 's trailing twelve months Income from Cont. Operations growth was higher than company's average 37% and higher than 74.5% growth in Dec 31 2021.
But from the previous reporting period rise was slower at 9.12 % from $12358 millions reported in twelve months ending a quarter Dec 31 2021 Melissa Hall continued.
Still this was confirmation of convincing trend, as the typical sequential Income from Cont. Operations gain stands at 7.94%.
The momentum is even more impressive sequentially clinched at 9.12 % increase from $12358 millions in twelve months ending a quarter before.

Within the Healthcare sector 34 other companies have achieved higher trailing twelve month Income from Cont. Operations growth. While Total ranking has impoved so far to 430, from total ranking in previous quarter at 480.

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
146.86 %
7.94 %
-87.73 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 22
Healthcare Sector # 35
Overall # 430

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
575.58 %
37 %
-92.46 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 22
Sector # 57
S&P 500 # 714
Cumulative Income from Cont. Operations growth Comment
Merck And Co Inc saw improvement in Income from Cont. Operations growth trend, posting cumulative 12 months Income from Cont. Operations growth of 91.3% year on year, to $ 13,485 millions if the fiscal year would have ended in Mar 31 2022.
Merck And Co Inc 's trailing twelve months Income from Cont. Operations growth was higher than company's average 37% and higher than 74.5% growth in Dec 31 2021.
But sequential growth rate was slower at 9.12 % from $12358 millions recorded in twelve months ending a quarter before.
In spite of, it was validation of positive momentum, as the typical Q/Q TTM Income from Cont. Operations advancement lays at 7.94%.
The growth was even more impressive from the previous reporting period clinched at 9.12 % jump from $12358 millions in twelve months ending a quarter Dec 31 2021.

Within the Healthcare sector 34 other companies have achieved higher trailing twelve month Income from Cont. Operations growth. While Total ranking has impoved so far to 430, from total ranking in previous quarter at 480.

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
146.86 %
7.94 %
-87.73 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 22
Healthcare Sector # 35
Overall # 430

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
575.58 %
37 %
-92.46 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 22
Sector # 57
S&P 500 # 714




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
MRK's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for MRK's Competitors
Income from Cont. Operations Growth for Merck And Co Inc 's Suppliers
Income from Cont. Operations Growth for MRK's Customers

You may also want to know
MRK's Annual Growth Rates MRK's Profitability Ratios MRK's Asset Turnover Ratio MRK's Dividend Growth
MRK's Roe MRK's Valuation Ratios MRK's Financial Strength Ratios MRK's Dividend Payout Ratio
MRK's Roa MRK's Inventory Turnover Ratio MRK's Growth Rates MRK's Dividend Comparisons



Companies with similar Income from Cont. Operations jump for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Mar 31 2022
Repligen Corp59.47%$ 59.470 millions
Conmed Corporation51.88%$ 51.876 millions
Becton Dickinson And Company51.33%$ 51.333 millions
Iqvia Holdings Inc 49.77%$ 49.770 millions
Charles River Laboratories International inc 48.94%$ 48.942 millions
Co diagnostics Inc 48.31%$ 48.305 millions
Phibro Animal Health Corp45.46%$ 45.457 millions
Abcellera Biologics Inc 43.81%$ 43.808 millions
Medpace Holdings Inc 41.58%$ 41.576 millions
Eli Lilly And Company40.40%$ 40.404 millions
Abbott Laboratories36.48%$ 36.475 millions
Merck and Co Inc 35.37%$ 35.374 millions
Bio techne Corp32.47%$ 32.470 millions
The Pennant Group Inc 26.83%$ 26.835 millions
Abbvie Inc 26.39%$ 26.385 millions
Tenet Healthcare Corp25.68%$ 25.676 millions
Glucotrack Inc.20.91%$ 20.907 millions
Syneos Health Inc 19.24%$ 19.244 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

LVAC's Profile

Stock Price

LVAC's Financials

Business Description

Fundamentals

Charts & Quotes

LVAC's News

Suppliers

LVAC's Competitors

Customers & Markets

Economic Indicators

LVAC's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071